DJ-17-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

AUDONNET et al.

Serial No.

10/085,519

For

POLYNUCLEOTIDE VACCINE FORMULA IN

PARTICULAR AGAINST BOVINE

RESPIRATORY PATHOLOGY

Filed

February 28, 2002

Examiner

Z. Lucas

Art Unit

1648

745 Fifth Avenue New York, NY 10151

MAR 2 7 2003

TECH CENTER 1600/2900

454313

EXPRESS MAIL

Mailing Label Number: EV 195878350 US

Date of Deposit:

March 17, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

AMENDMENT AND RESPONSE TO OFFICE ACTION WITH REQUEST FOR EXTENSION OF TIME

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

This is in response to the Office Action mailed on December 16, 2002, setting a one month term for reply.

PETITION FOR EXTENSION OF TIME

Pursuant to 37 C.F.R. §1.136(a) and §1.17(a), a two-month extension of the period for reply, i.e., to up to and including March 17, 2003 (as March 16 was a Sunday) is requested. The Commissioner is hereby authorized to charge the \$410.00 fee and any additionally required fee for this extension of time or any other fee occasioned by this paper, or credit any overpayment in such fees, to Deposit Account No. 50-0320.

-1-

03/21/2003 RMEBRAHT 00000096 500320

10085519

01 FC:1252

410.00 CH

00117347

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents. Attached is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

In the Claims

- 12. (Amended) An immunogenic composition for inducing an immunological response against bovine parainfluenza virus type 3 comprising at least one plasmid that contains and expresses *in vivo* in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding type 3 bovine parainfluenza virus HN protein, or F protein, or HN and F proteins.
- 13. (Amended) The immunogenic composition according to claim 12 which comprises a plasmid that contains and expresses *in vivo* in a bovine host cell a nucleic acid molecule having a sequence encoding bovine parainfluenza virus type 3 HN protein.
- 14. (Amended) The immunogenic composition according to claim 12 which comprises a plasmid that contains and expresses *in vivo* in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine parainfluenza virus type 3 F protein.
- 15. (Amended) The immunogenic composition according to claim 12 which comprises a plasmid that contains and expresses *in vivo* in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine parainfluenza virus type 3 HN and F proteins.
- 16. (Amended) A method for inducing an immunological response in a bovine comprising: administering to said bovine a vaccine selected from the group consisting of a live whole vaccine, an inactivated whole vaccine, a subunit vaccine, and a recombinant vaccine; and thereafter, administering to said bovine an immunogenic or vaccine composition as claimed in any one of claims 12-15.
- 17. (Amended) A method for inducing an immunological response in a bovine comprising administering to said bovine an immunogenic or vaccine composition as claimed in any one of claims 12-15.
- 18. (Amended) A kit comprising (i) an immunogenic composition according to any one of claims 12-15, and (ii) a bovine vaccine selected from the group consisting of a live whole vaccine, an inactivated whole vaccine, a subunit vaccine, and recombinant vaccine.